Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Three months af­ter a large study of No­vo Nordisk’s pop­u­lar weight-loss and di­a­betes in­jec­tion showed it cut ma­jor car­dio­vas­cu­lar risks by 20%, fur­ther re­sults from the tri­al showed how the drug af­fect­ed oth­er cru­cial out­comes like heart fail­ure and death.

No­vo re­leased topline da­ta from the study in Au­gust, not­ing at that time that it planned to file for a la­bel ex­pan­sion in the US and EU this year. The vast SE­LECT tri­al, which en­rolled 17,604 pa­tients, is one of the largest and longest stud­ies — 4 1/2 years — in­ves­ti­gat­ing the GLP-1 in adults. Par­tic­i­pants were 45 years old or old­er, didn’t have di­a­betes, were over­weight or obese, and had a di­ag­no­sis of car­dio­vas­cu­lar dis­ease. They got ei­ther a place­bo, or 2.4 mg of semaglu­tide, which is ap­proved as We­govy for weight loss and Ozem­pic for type 2 di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER